Cargando…
Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?
Autores principales: | Zuin, Marco, Cervellati, Carlo, Rigatelli, Gianluca, Zuliani, Giovanni, Roncon, Loris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594077/ https://www.ncbi.nlm.nih.gov/pubmed/34801920 http://dx.doi.org/10.1016/j.thromres.2021.11.008 |
Ejemplares similares
-
Corticosteroid therapy in COVID-19 patients: Don’t forget venous thromboembolism
por: Roncon, Loris, et al.
Publicado: (2021) -
Ongoing trials on COVID-19 treatments: please, don’t forget Venous Thromboembolism!
por: Zuin, Marco, et al.
Publicado: (2021) -
Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis
por: Zuin, Marco, et al.
Publicado: (2022) -
Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis
por: Zuin, Marco, et al.
Publicado: (2021) -
Age-adjusted d-dimer cut-off levels to exclude venous thromboembolism in COVID-19 patients
por: Zuin, Marco, et al.
Publicado: (2021)